Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

Jianfeng Zheng; Wenjuan Chen; Xuemei Yi; Ning Yu; Yangfeng Ding; Yunlu Gao

doi:10.3389/fmed.2023.1285972

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

Front Med (Lausanne). 2023 Dec 14:10:1285972. doi: 10.3389/fmed.2023.1285972. eCollection 2023.

Authors

Jianfeng Zheng^{1

2}, Wenjuan Chen^{1

2}, Xuemei Yi^{1

2}, Ning Yu^{1

2}, Yangfeng Ding^{1

2}, Yunlu Gao^{1

2}

Affiliations

¹ Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
² Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.

Abstract

Background: Randomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.

Objectives: This work aimed to assess the long-term effectiveness of guselkumab in actual clinical practice in China.

Methods: A retrospective study was performed for plaque psoriasis cases administered guselkumab in Shanghai Skin Disease Hospital between January 2020 and September 2022.

Results: A total of 37 patients were included (29 men, 78.4%), with a mean follow-up period of 72.3 ± 26.7 weeks (range of 12-108 weeks). At baseline, clinical examination revealed a mean PASI of 12.3 ± 7.1, a mean BSA of 17.1 ± 18.1, and a mean DLQI of 7.7 ± 4.3. Twenty-two (62.9%) and 17 (48.6%) cases achieved PASI 90 and PASI 100 responses at week 28. From weeks 60 to 92, >80% of cases achieved PASI 90 and PASI 100 responses. Regarding safety, no cases of serious AEs were recorded. A total of nine cases (24.3%) had different abnormal results in HBV markers, and two were T-SPOT positive. There was no hepatitis B virus or tuberculosis outbreak in these patients.

Conclusion: This real-life study confirmed the long-term efficacy and safety of guselkumab in daily clinical practice.

Keywords: Chinese patients; efficacy; guselkumab; plaque psoriasis; real-life; safety.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by the Clinical Research Plan of SHDC (SHDC2020CR1014B).